A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial
Location: CPMC (San Francisco)
Please contact email@example.com about the QED Cholangiocarcinoma Proof trial
View study details on ClinicalTrials.gov
August 23, 2019
Investigator(s): Ellis C. Dillon, Ph.D.
Breast Tumor and Blood markers for Molecular Diagnosis of Breast Diseases and Monitoring of Breast Cancer Treatment and Follow-up
Investigator(s): Su-Ying Liang, Ph.D.